belapectin

Polysaccharide

Negativelead readout

Evidence outlook · lead readout

NAVIGATE (NCT04365868) · Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis

The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.

NAVIGATE (NCT04365868): This was a randomized, double-blind, placebo-controlled trial in 355 patients with MASH cirrhosis, with a clinical primary endpoint: a composite of new esophageal varices or intercurrent events at 18 months. The registry counts show fewer patients with new varices on belapectin (45 of 119 on 2 mg/kg, 51 of 118 on 4 mg/kg) than on placebo (56 of 118). The sponsor reports that the composite primary endpoint did not reach statistical significance in the intent-to-treat population. A pre-defined per-protocol analysis (290 patients) showed a 48.9% reduction in varices with 2 mg/kg (p<0.05); it does not change the primary result.

Caveat: the arm counts are from the trial registry; the statistical-significance call and the per-protocol result are the sponsor's own statement in its topline announcement.

Also in development:NASH Cirrhosis · Phase 2/3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
NASH Cirrhosis
Phase 2 (4)
MASH / NASH
NASH Cirrhosis
NCT02462967 · Galectin Therapeutics Inc.
2015-06 – 2017-10 · Hypertension, Portal
What this study did
Other / comorbidity
NCT04987996 · Providence Health & Services
2023-07-01 – 2031-07-01 · Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
What this study did
NCT02407041 · Galectin Therapeutics Inc.
2015-09 – 2018-03 · Psoriasis
What this study did
Phase 1 (4)
MASH / NASH
Other / comorbidity
NCT02575404 · Providence Health & Services
2016-05-16 – 2022-10-10 · Melanoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT04332432 · Galectin Therapeutics Inc.
2020-06-16 – 2022-03-09 · Hepatic Impairment
What this study did
NCT02117362 · Providence Health & Services
2014-05-08 – 2018-11-28 · Metastatic Melanoma
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for MASH / NASH: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Belapectin: this drugPhase 2/3PolysaccharideGalectin-3Partial signal
NCT04365868: Proportion of patients with new esophageal varices at 78 weeks (registry): belapectin 2 mg/kg 45/119, belapectin 4 mg/kg 51/118 vs placebo 56/118. The sponsor reports that the composite primary endpoint did not reach statistical significance in the intent-to-treat population (n=355); in the pre-defined per-protocol population (n=290), the 2 mg/kg group showed a 48.9% reduction in varices (p<0.05). missed
NCT02421094: Mean Change in Liver Fibrosis of Corrected T1 (cT1) Mapping (LiverMultiScan -LMS) (16 weeks): GR-MD-02 8 mg/kg 19.15 milliseconds (ms) (95% CI -7.7 to 43.5) vs Placebo 1.25 milliseconds (ms) (95% CI -7.7 to 43.5) missed
Resmetirom (Rezdiffra)ApprovedSmall moleculeThyroid hormone receptor-betaPartial signal
NCT03900429: Month-12 histology (n=888): MASH resolution without fibrosis worsening 26-27% (80 mg) and 24-36% (100 mg) vs 9-13% placebo; fibrosis improvement without MASH worsening 23% (80 mg) and 24-28% (100 mg) vs 13-15% placebo (ranges across the two pathologists); both endpoints statistically significant for both doses (REZDIFFRA label, Trial 1).
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
ALN-CIDEBPhase 3RNA / oligonucleotideCIDEBnot yet gradedNo reviewed efficacy summary in this indication
AramcholPhase 3—Stearoyl-CoA desaturase 1 (SCD1)not yet gradedNo reviewed efficacy summary in this indication
Efimosfermin AlfaPhase 3Protein / enzyme therapeuticFGF21 receptorWeak signalFeatured results are safety only in this race
LanifibranorPhase 3Small moleculePeroxisome proliferator-activated receptors (PPARs), PPAR (pan-agonist)Partial signalNo reviewed efficacy summary in this indication
PegozaferminPhase 3Protein / enzyme therapeuticFGFR1c/2c/3c–β-Klotho agonistnot yet gradedNo reviewed efficacy summary in this indication
PemvidutidePhase 3PeptideGLP-1/glucagon receptor (dual)Partial signal
NCT05989711: Co-primary endpoints at week 24 (ITT): MASH resolution without fibrosis worsening 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001); fibrosis improvement without MASH worsening 31.8% and 34.5% vs 25.9%, not statistically significant (HCPLive, 2025-06-26).
SurvodutidePhase 3PeptideGLP-1/glucagon receptor (dual)Reliable signal
NCT06309992: Co-primary 1, ≥30% reduction in MRI-PDFF liver fat content at week 48: 84.2% survodutide 6.0 mg vs 24.3% placebo (efficacy estimand, P<0.0001; treatment regimen estimand 68.5% vs 28.6%, P<0.0001), met. Co-primary 2, percentage change in body weight at week 48: -12.2% vs -1.0% (efficacy estimand, P<0.0001; treatment regimen estimand -8.7% vs -1.4%, P<0.0001), met.
ALG-055009Phase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
ALN-PNPPhase 2RNA / oligonucleotidePNPLA3Weak signalNo reviewed efficacy summary in this indication
DenifanstatPhase 2Small moleculeFatty acid synthase (FASN), FASNReliable signal
NCT04906421: Histological Improvement in Nonalcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) Without Worsening of Fibrosis (by NASH Clinical Research Network [CRN] Fibrosis Score). (52 Weeks): ITT: TVB-2640 50 mg 42/112 | mITT: TVB-2640 50 mg 42/81 vs ITT: Placebo 9/56 | mITT: Placebo 9/45
NCT03938246: Relative change in liver fat (MRI-PDFF) at week 12 vs placebo (+4.5%): -9.6% with 25 mg (LS mean difference -15.5%; 95% CI -31.3 to -0.23; P=.053) and -28.1% with 50 mg (LS mean difference -28.0%; 95% CI -44.5 to -11.6; P=.001) (FASCINATE-1, Gastroenterology 2021).
ECC4703Phase 2—Thyroid hormone receptor beta (THRβ)not yet gradedNo reviewed efficacy summary in this indication
EfinopegdutidePhase 2PeptideGLP-1/glucagon receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
EfocipegtrutidePhase 2PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
ErvogastatPhase 2Small moleculeDiacylglycerol acyltransferase 2 (DGAT2)Partial signal
NCT04321031: Mean Proportion of Participants Achieving Resolution of NASH Without Worsening/Improvement of Fibrosis by >=1 Stage Without Worsening of NASH/Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48:Bayesian Dose Response Model (BDRM) (Week 48): DGAT2i/PF-06865571 25 mg BID 45% (95% CI 38% to 53%) | DGAT2i/PF-06865571 75 mg BID 48% (95% CI 42% to 55%) | DGAT2i/PF-06865571 150 mg BID 50% (95% CI 43% to 57%) | DGAT2i/PF-06865571 300 mg BID 51% (95% CI 43% to 59%) vs Placebo 38% (95% CI 26% to 50%)
NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89)
GatuzosiranPhase 2RNA / oligonucleotideHSD17B13Weak signal
NCT06104319: Predicted mean change from baseline in HSD17B13 protein expression at Week 28: -26.82% (25 mg), -61.82% (200 mg), -70.02% (400 mg), -75.27% (800 mg)
NCT04202354: Treatment-related TEAEs: 0/4 with ARO-HSD 25 mg, 0/4 with 50 mg, 1/4 with 100 mg, and 3/4 with 200 mg versus 0/16 with pooled placebo.
HU6Phase 2Small moleculeMitochondrial uncouplingnot yet gradedNo reviewed efficacy summary in this indication
MiricorilantPhase 2Small moleculeGlucocorticoid receptorWeak signal
NCT05117489: Open-label study in patients with presumed non-alcoholic steatohepatitis: patients who received 100 mg of miricorilant orally every Monday and Friday for 12 weeks experienced an approximately 30 percent reduction in liver fat as assessed by MRI-PDFF and showed improvements in liver enzymes and markers of liver disease.
NamodenosonPhase 2—Adenosine A3 receptorPartial signal
NCT02927314: Change from baseline in serum ALT at Week 12, namodenoson 25 mg b.d. vs placebo: P=0.066 (trend, not statistically significant) missed
ORMD-0801Phase 2PeptideInsulinnot yet gradedNo reviewed efficacy summary in this indication
Rapirosiran (ALN-HSD)Phase 2RNA / oligonucleotideHSD17B13Weak signalFeatured results are safety only in this race
TB006
Phase 2(overall)
Monoclonal antibodyGalectin-3
not yet graded(overall)
No reviewed efficacy summary in this indication
TipelukastPhase 2Small moleculeCysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenasenot yet gradedNo reviewed efficacy summary in this indication
VanoglipelPhase 2Small moleculeGPR119not yet gradedNo reviewed efficacy summary in this indication
VK2809Phase 2Small moleculeThyroid hormone receptor-betaPartial signal
NCT04173065: Primary: liver fat reduction (MRI-PDFF) at Week 12, mean relative change -45.3% (2.5 mg QD), -36.8% (5 mg QOD), -51.7% (10 mg QOD), each p<0.0001 vs placebo. Secondary, 52-week biopsy: NASH resolution with no worsening of fibrosis 63% to 75% vs 29% placebo (p<0.05 each arm); >=1-stage fibrosis improvement with no worsening of NASH 44% to 57% vs 34% placebo (p<0.05 for the 5 mg and 10 mg QOD arms only).
NCT02927184: Primary endpoint, placebo-adjusted % change in LDL-C at week 12: VK2809 10mg every-other-day -23.6% (p=0.0121); VK2809 10mg daily -20.2% (p=0.0269); combined VK2809 -21.8% (p=0.0061).
VonafexorPhase 2Small moleculeFarnesoid X receptor (FXR/NR1H4)Partial signal
NCT03812029: Analysis of Absolute Change From Baseline in Percentage of Fat in the Liver as Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) (12 weeks): Vonafexor 100 mg QD Part B -6.3% (95% CI -8.1 to -4.5) | Vonafexor 200 mg QD Part B -5.4% (95% CI -7.2 to -3.6) vs Placebo Part B -2.3% (95% CI -4 to -0.6) | Placebo Part A 3.9% (95% CI -2.5 to 10.4)
ZabopegdutidePhase 2PeptideGLP-1/glucagon receptor (dual)Partial signal
NCT06410924: Proportion of subjects achieving at least 30% liver fat reduction by MRI-PDFF at 12 weeks: 75.8% (DD01) vs 11.8% (placebo); p<0.0001.
OPK-88006Phase 1/2—GLP-1/glucagon receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ARO-PNPLA3
Phase 1(overall)
RNA / oligonucleotidePNPLA3not yet gradedNo reviewed efficacy summary in this indication
AZD2389
Phase 1(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BI 3006337Phase 1——Weak signalFeatured results are safety only in this race
BI 3804379Phase 1——not yet gradedNo reviewed efficacy summary in this indication
SIF001
Phase 1(overall)
Monoclonal antibodyGalectin-3
not yet graded(overall)
No reviewed efficacy summary in this indication
ZT003
Phase 1(overall)
PeptideFGF21/GLP-1 receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
MGL-2086
—(overall)
Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
NNC4005-001
—(overall)
RNA / oligonucleotideSLC25A5not yet gradedNo reviewed efficacy summary in this indication
AZD7503DiscontinuedRNA / oligonucleotideHSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) mRNAWeak signalNo reviewed efficacy summary in this indication
ClesacostatDiscontinuedSmall moleculeAcetyl-CoA carboxylase (ACC1/ACC2)Partial signal
NCT04321031: Number of Participants Achieving Resolution of NASH Without Worsening or Improvement in Fibrosis by >= 1 Stage Without Worsening of NASH or Both Based on Assessment by Sponsor-Identified Central Pathologist at Week 48: Logistic Regression Model (Week 48): DGAT2i/PF-06865571 150 mg BID + ACCi/PF-05221304 5 mg BID 23/35 | DGAT2i/PF-06865571 300 mg BID + ACCi/PF-05221304 10 mg BID 19/30 vs Placebo 13/34 | DGAT2i/PF-06865571 25 mg BID 16/35 | DGAT2i/PF-06865571 75 mg BID 25/48 | DGAT2i/PF-06865571 150 mg BID 21/42 | DGAT2i/PF-06865571 300 mg BID 14/31
NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89)
Obeticholic Acid (Ocaliva)Discontinued—FXRnot yet gradedNo reviewed efficacy summary in this indication
Omega-3-Carboxylic Acids (Epanova)DiscontinuedSmall moleculePeroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptornot yet gradedNo reviewed efficacy summary in this indication
PF-05221304 + PF-06865571DiscontinuedSmall moleculeAcetyl-CoA carboxylase (ACC1/ACC2) + Diacylglycerol acyltransferase 2Partial signal
NCT03776175: Percent Change From Baseline in Whole Liver Proton Density Fat Fraction (PDFF) at Day 42 (Baseline, Day 42): PF-05221304 15mg + Placebo -40.01% (95% CI -47 to -32.09) | PF-06865571 300 mg + Placebo -30.14% (95% CI -37.97 to -21.33) | PF-05221304 15 mg + PF-06865571 300 mg -40.13% (95% CI -46.58 to -32.9) vs Placebo 8.14% (95% CI -8.56 to 27.89)
Rosiglitazone (Avandia)DiscontinuedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 December 2024Topline resultNAVIGATE Phase 2b/3 topline results
Galectin Therapeutics · Source ↗